Search
Jazz Pharmaceuticals PLC
JAZZAdd to Watchlist
252.860USD
-5.520-2.14%
Close 07-31 16:00（ET）Quotes delayed by 15 min
15.53BMarket Cap
613.23P/E TTM
More Details of Jazz Pharmaceuticals PLC Company
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC Info
Ticker SymbolJAZZ
Company nameJazz Pharmaceuticals PLC
IPO dateJan 18, 2012
CEOGala (Renee D)
Number of employees2800
Security typeOrdinary Share
Fiscal year-endJan 18
AddressFifth Floor, Waterloo Exchange
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal code- -
Phone35316347800
Websitehttps://www.jazzpharma.com/
Ticker SymbolJAZZ
IPO dateJan 18, 2012
CEOGala (Renee D)
Company Executives of Jazz Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
FAQs
Who are the top five shareholders of Jazz Pharmaceuticals PLC?
The top five shareholders of Jazz Pharmaceuticals PLC are: Mr. Seamus C. Mulligan
How many institutions hold shares of Jazz Pharmaceuticals PLC (JAZZ)?
As of 2026Q1, 1229 institutions hold shares of Jazz Pharmaceuticals PLC, with a combined market value of approximately 70.31M, accounting for 112.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -754072.00.
What is the biggest source of revenue for Jazz Pharmaceuticals PLC?
In 2026Q1, the Xywav business generated the highest revenue for Jazz Pharmaceuticals PLC, amounting to 1.66B and accounting for 38.83% of total revenue.